{"slug":"deal-asset","tag":"deal-asset","variants":["deal-asset"],"description":"No description yet","count":10,"kinds":{"drug":10},"related":[{"slug":"pipeline","tag":"pipeline","shared":10}],"records":[{"id":"avzo-1418","kind":"drug","name":"AVZO-1418","route":"/drugs/avzo-1418/","status":"phase-2","tldr":"AVZO-1418 is an experimental antibody-drug conjugate that targets two proteins, EGFR and HER3, on cancer cells. Avenzo Therapeutics licensed it from DualityBio and is testing it in a first phase 1/2 trial in advanced solid tumours."},{"id":"lm-299","kind":"drug","name":"LM-299","route":"/drugs/lm-299/","status":"phase-2","tldr":"LM-299 is an experimental antibody that blocks two things at once: PD-1, a brake on the immune system, and VEGF, which feeds tumour blood vessels. LaNova Medicines discovered it and Merck licensed it in 2024, where it is called MK-2010."},{"id":"yl211","kind":"drug","name":"YL211","route":"/drugs/yl211/","status":"phase-1","tldr":"YL211 is an experimental antibody-drug conjugate aimed at c-MET, a protein on some solid tumours. MediLink Therapeutics licensed worldwide rights to Roche in January 2024, and it is in a first phase 1 trial."},{"id":"ibi3009","kind":"drug","name":"IBI3009","route":"/drugs/ibi3009/","status":"phase-1","tldr":"IBI3009 is an experimental antibody-drug conjugate for small cell lung cancer, aimed at the protein DLL3. Innovent Biologics licensed it to Roche in January 2025, and it is in a first phase 1 trial."},{"id":"lb2102","kind":"drug","name":"LB2102","route":"/drugs/lb2102/","status":"phase-1","tldr":"LB2102 is an experimental CAR-T cell therapy for small cell lung cancer, made from a patient's own immune cells and aimed at the protein DLL3. Legend Biotech licensed it to Novartis in November 2023."},{"id":"shr-4849","kind":"drug","name":"SHR-4849","route":"/drugs/shr-4849/","status":"phase-2","tldr":"SHR-4849, called IDE849 by IDEAYA Biosciences, is an experimental antibody-drug conjugate aimed at the protein DLL3 in small cell lung cancer and neuroendocrine tumours. Hengrui discovered it and licensed rights outside Greater China to IDEAYA in December 2024."},{"id":"shr-a1904","kind":"drug","name":"SHR-A1904","route":"/drugs/shr-a1904/","status":"phase-3","tldr":"SHR-A1904 is Hengrui's experimental antibody-drug conjugate aimed at Claudin 18.2, in a phase 3 trial against standard second-line treatment for advanced stomach cancer. Merck KGaA holds an option to license it outside China."},{"id":"arx517","kind":"drug","name":"ARX517","route":"/drugs/arx517/","status":"phase-1","tldr":"ARX517 is an experimental antibody-drug conjugate for metastatic prostate cancer, aimed at the protein PSMA. Ambrx developed it and Johnson & Johnson took it over when it bought Ambrx in 2024."},{"id":"tulmimetostat","kind":"drug","name":"Tulmimetostat","route":"/drugs/tulmimetostat/","status":"phase-2","tldr":"Tulmimetostat is an experimental tablet that blocks the gene-silencing enzymes EZH1 and EZH2. Novartis gained it by buying MorphoSys in 2024 and is testing it in prostate cancer, lymphomas and other solid tumours."},{"id":"pnt2003","kind":"drug","name":"Lutetium Lu 177 dotatate (PNT2003)","route":"/drugs/pnt2003/","status":"emerging","tldr":"PNT2003 is a generic version of Lutathera, the radioactive treatment for neuroendocrine tumours of the gut and pancreas. Lantheus licensed it from POINT Biopharma and received tentative FDA approval in March 2026; full approval was waiting on a patent dispute."}]}